Fri. 5 Apr 2024, 4:49pm ET
Benzinga
Earnings, Earnings Beats, News
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.23) by 30.43 percent. This is a 40.74 percent increase over losses of $(0.27) per share from the same period last year.